WE ARE CASI
An innovative biopharmaceutical company developing an anti-CD38 monoclonal antibody treatment for organ transplant rejection and autoimmune diseases.
TRANSPLANT PATIENTS CAN'T WAIT
Despite recent advancements in organ transplantation, antibody-mediated rejection (AMR) remains an urgent unmet medical need. Among kidney transplant patients, for example, approximately 12% experience acute or chronic AMR—affecting more than 30,000 people in the United States alone. Currently, there is no FDA-approved treatment for AMR. At CASI, we are striving to bring a first-in-class and best-in-class therapy to alleviate the burden of AMR on affected patients.
FOCUSED ON DEVELOPING CID-103
CID-103 is an investigational monoclonal antibody. Its targets include B memory, plasmablasts, and B plasma cells. The anti-CD38 approach aims to address limitations seen with CD19 and CD20-targeted therapies, which do not deplete persistent plasma cells—cells that may contribute to organ transplant rejection by generating antibodies which attack the donor kidney.
Peer-reviewed medical literature, including important articles in the New England Journal of Medicine, point to the promise of the anti-CD38 approach in organ transplant and also autoimmune diseases such as immune thrombocytopenia (ITP).
Join Us in Transforming Transplant Care and Autoimmune Disease
At CASI Pharmaceuticals, we believe that patients who have received organ transplant patients can’t wait. With CID-103, we are carrying out important research and development to address the urgent unmet needs of antibody-mediated rejection and autoimmune disease. Our commitment to innovation and patient-centric care drives us forward.